Dr. John A. Bernat, MD,PHD
Medical Genetics (Clinical Genetics (M.D.) Physician)
At a glance
- Years since graduation
- 17
- In the NPI registry since
- 2009
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Clinical Genetics (M.D.) Physician primary
IA license MD-42475 -
Clinical Molecular Genetics Physician
IA license MD-42475 -
Pediatrics Physician
IA license MD-42475
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Iowa Hospital & Clinics Iowa City, IA
Medical groups
- State University of Iowa (1,897 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Payments from drug and device companies
In 2025, 1 companies reported 10 payments worth $10,511 in total to this clinician.
| Chiesi USA, Inc. | $10,511 |
|---|
| Honoraria | $4,600 |
|---|---|
| Consulting Fee | $4,025 |
| Travel and Lodging | $1,580 |
| Food and Beverage | $305 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Chiesi USA, Inc. Jul 24, 2025 | Honoraria ELFABRIO · ERT FOR FABRY DISEASE | $4,600 |
| Chiesi USA, Inc. Feb 20, 2025 | Consulting Fee ELFABRIO · ERT FOR FABRY DISEASE | $4,025 |
| Chiesi USA, Inc. Feb 27, 2025 | Travel and Lodging ELFABRIO · ERT FOR FABRY DISEASE · travel to SAN DIEGO, CA | $710 |
| Chiesi USA, Inc. Jul 11, 2025 | Travel and Lodging ELFABRIO · ERT FOR FABRY DISEASE · travel to DETROIT, MI · in-kind | $584 |
| Chiesi USA, Inc. Jul 11, 2025 | Travel and Lodging ELFABRIO · ERT FOR FABRY DISEASE · travel to DETROIT, MI · in-kind | $240 |
| Chiesi USA, Inc. Jul 24, 2025 | Travel and Lodging ELFABRIO · ERT FOR FABRY DISEASE · travel to DETROIT, MI | $45.66 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $314,006 in research payments for these studies, mostly to the institutions running them.
- A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy
Takeda Pharmaceuticals U.S.A., Inc. · Completed · NCT03771898 - Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3
Sanofi US Services Inc. · Active, not recruiting · NCT05222906 - Fabry Disease Registry & Pregnancy Sub-registry
Sanofi US Services Inc. · Recruiting · NCT00196742 - International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
Sanofi US Services Inc. · Recruiting · NCT00358943
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.